Scarica l'app Stockscreener
29.88
1.52%
-0.46
Dopo l'orario di chiusura:
29.94
0.06
+0.20%
Uniqure N V Borsa (QURE) Ultime notizie
uniQure NV Hits Day High with 15.18% Surge Amid Market Volatility - Markets Mojo
Can uniQure N.V. (UQ1) stock sustain revenue momentumRisk Management & Daily Profit Maximizing Tips - newser.com
uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Yahoo Finance
Volatility clustering patterns for uniQure N.V.Earnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
How institutional buying supports uniQure N.V. stock2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
What catalysts could drive uniQure N.V. stock higherJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Why uniQure N.V. stock is rated strong buyWeekly Gains Report & Verified Entry Point Detection - Fundação Cultural do Pará
Predicting uniQure N.V. trend using moving averagesMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
UniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsQURE - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
Risk adjusted return profile for uniQure N.V. analyzedRate Cut & Daily Profit Maximizing Trade Tips - newser.com
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
FDA Unveils New Path for Approving Rare Disease Drugs for Just One Person - Bloomberg.com
What data driven models say about uniQure N.V.’s future2025 Momentum Check & Daily Stock Trend Reports - newser.com
Makary, Prasad outline pathway for bespoke gene therapy - statnews.com
Uniqure’s CEO dined with investors. Here’s what he said - statnews.com
Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Yahoo Finance
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Investors to Connect - ACCESS Newswire
uniQure (QURE): Wells Fargo Adjusts Price Target to $60, Maintai - GuruFocus
Can uniQure N.V. stock hit record highs againJuly 2025 Selloffs & Short-Term High Return Ideas - newser.com
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
uniQure NV Hits Day High with 17.93% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - Insider Monkey
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $45 to $60 - 富途牛牛
Liquidity Mapping Around (QURE) Price Events - news.stocktradersdaily.com
uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP - The AI Journal
uniQure’s Bumpy Ride: Stock Price Prospects - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages uniQure N.V. (QURE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure N.V. (NASDAQ:QURE) Q3 2025 Earnings Call Transcript - Insider Monkey
Chardan Capital Maintains 'Buy' Rating on QURE with $53 Price Ta - GuruFocus
Leerink Partners Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
UniQure: Q3 Earnings Snapshot - ctinsider.com
William Blair reiterates Market Perform rating on uniQure stock amid AMT-130 uncertainty - Investing.com UK
UniQure outlines urgent FDA engagement for AMT-130 as BLA timing turns uncertain - MSN
10 Stocks on a Hot Streak - Insider Monkey
Decoding uniQure NV (QURE): A Strategic SWOT Insight - GuruFocus
uniQure Reports Q3 2025 Results and Clinical Progress - TipRanks
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Uniqure NV earnings missed by $0.47, revenue fell short of estimates - Investing.com South Africa
uniQure N.V. Earnings Call: Pipeline Progress Amid Challenges - TipRanks
QURE: Leerink Partners Lowers Price Target, Maintains Outperform Rating | QURE Stock News - GuruFocus
uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Da - GuruFocus
uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges - Yahoo Finance
uniQure (QURE) Faces Uncertainty in BLA Submission Despite Positive AMT-130 Data - GuruFocus
From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside (NASDAQ:QURE) - Seeking Alpha
uniQure (QURE) Reveals Promising Data Amid Regulatory Challenges - GuruFocus
uniQure (QURE) Q3 2025 Earnings Call Transcript - AOL.com
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates - sharewise.com
1.43%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):